• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (2)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Pacemakers/ Defibrillators  • Cardiovascular System  • Women's Health  • Women's Health, Other  • Arrhythmias  • Cardiovascular Disease/ Myocardial Infarction  • Alert me on articles by topic  Social Bookmarking   What's this?

Rita F. Redberg, MD

Arch Intern Med. 2009;169(16):1460-1461.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The use of implantable cardioverter- defibrillators (ICDs) has grown rapidly in the last decade. Originally reserved for only the highest-risk patients such as survivors of sudden cardiac death (SCD), use of ICDs has expanded to include primary prevention following the publication of 2 randomized clinical trials establishing their efficacy.^1-2 Since then, the great challenge in ICD use has been to identify those at greatest risk for SCD—that is, the population who would benefit the most from implantation. Cardiologists have used various criteria, such as the width of QRS and T-wave alternans, for risk stratification. Meanwhile, the use of ICDs has expanded even beyond those with heart failure to include younger patients with such conditions as arrhythmogenic right ventricular dysplasia, long QT syndrome, and hypertrophic cardiomyopathy.³

Approximately 30% of ICD recipients are women.⁴ However, data supporting the efficacy of ICDs for primary prevention in women is sparse.⁵ . . . [Full Text of this Article]

AUTHOR INFORMATION


CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Effectiveness of Implantable Cardioverter-Defibrillators for the Primary Prevention of Sudden Cardiac Death in Women With Advanced Heart Failure: A Meta-analysis of Randomized Controlled Trials
Hamid Ghanbari, Ghassan Dalloul, Reema Hasan, Marcos Daccarett, Souheil Saba, Shukri David, and Christian Machado
Arch Intern Med. 2009;169(16):1500-1506.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Meta-Analysis of Statin Effects in Women Versus Men
Kostis et al.
J Am Coll Cardiol 2012;59:572-582.
ABSTRACT | FULL TEXT  

Clinical Trial Enrollment and Progress in Women's Health
Dhruva and Redberg
JAMA 2011;305:1197-1197.
FULL TEXT  

Gender Bias in Studies for Food and Drug Administration Premarket Approval of Cardiovascular Devices
Dhruva et al.
Circ Cardiovasc Qual Outcomes 2011;4:165-171.
ABSTRACT | FULL TEXT  

Do ICDs Work Better for Men Than for Women?
JWatch Women's Health 2009;2009:6-6.
FULL TEXT